DDIT3 and diffuse large B-cell lymphoma: Based on these findings, we have initiated a phase I trial with a dose expansion at the recommended phase II dose (VALFRID: Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma [10]).